November 2015, Vol. 2, No. 6

← Back to Issue

Exploring the Possibilities of Manipulating the Immune System to Improve Outcomes

Sanjiv S. Agarwala, MD

Letter to Our Readers

Dear Colleague,

We are pleased to continue our in-depth coverage of the role of immunotherapy in oncology care. Immunotherapy has long captured the interest of researchers combating disease, and none more so than oncology researchers. Recent advances in immunotherapy have made headlines and been the main attraction at association meetings. It is our mission to explore the topic diligently and thoroughly in the hope of providing our readership with information that will help improve and extend the life of patients with cancer.

In this issue, we present an interview with Elizabeth I. Buchbinder, MD, of Dana-Farber Cancer Institute about her research addressing the question of optimal sequencing of immunotherapeutic agents for patients with metastatic melanoma and metastatic renal cell carcinoma. Her research specifically addresses the efficacy and safety of high-dose interleukin-2 given after CTLA-4–targeting agents or other immune checkpoint blockade agents.

We also provide an in-depth article about targeting PD-1 and its ligand PD-L1. It is our hope this report provides increased awareness about the possibilities of manipulating the immune system to effectively combat cancers.

As always, we survey the vast amounts of information coming out of association meetings and bring you relevant and potentially clinically impactful stories. In this issue, you will read about important immuno-oncology information from the European Cancer Congress, American Society of Gene and Cell Therapy, International Lung Cancer Congress, and our own World Cutaneous Malignancies Congress.

Thank you for your loyal readership. We wish you success in your quest to provide the best care for your patients and hope your awareness and understanding of immunotherapy options is enhanced by our offerings.

Best regards,

Sanjiv S. Agarwala, MD
Editor in Chief
Immunotherapy in Oncology

16th International Lung Cancer Congress - November 9, 2015

Immunotherapy Will Alter the NSCLC Treatment Landscape

Despite the promise of molecular profiling, approximately 80% of patients with lung cancer lack a defined genotypic mutation and thus become resistant when treated with a tyrosine kinase inhibitor. According to data presented at the congress, however, lung cancer remains a highly mutated disease, suggesting great potential for immunotherapy. “If [ Read More ]

WCMC - November 9, 2015

Genetic Testing for Melanoma: What’s State of the Art?

Genetic testing in metastatic melanoma should include testing for all actionable mutations in exon 15, said Grant McArthur, MB, BS, PhD, at the 2015 World Cutaneous Malignancies Congress. Testing at the time of disease progression is not yet ready for routine clinical use. Test the Metastases In metastatic melanoma, tumor [ Read More ]